A modern, rational approach to a large class of proteins broadly relevant for pharmacology is enabling both from a postgenomic perspective and for reasons of economy of scale. The international public–private consortia RESOLUTE (https://re-solute.eu/) and REsolution (https://re-solute.eu/resolution) are generating a systematic functional assignment of each of the 451 different human solute carrier (SLC) proteins and, at the same time, trying to catalog and interpret the associated main genetic variants.

SLCs are a superfamily of facilitative and secondary active transporters, subclassified by sequence homology, and represent an understudied target class relevant both as source of drug targets (e.g., glifozins, selective serotonin reuptake inhibitors) and for drug disposition (e.g., organic anion transporters).^{1, 2} What if we were to take such a target class and wanted to rapidly “unlock” it for the scientific community to explore more broadly and easily? How would one go about it in a rational, postgenomic way? This is what RESOLUTE and REsolution, two public–private partnership projects funded by the Innovative Medicine Initiative (IMI, https://www.ihi.europa.eu/) of the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA), are well underway doing. Here we report on the status of the two programs, describe access to new public resources of data and reagents, and briefly describe what may be applicable for similar target class-wide efforts in the future.

从后基因组的角度和出于规模经济的原因，对与药理学广泛相关的一大类蛋白质的现代、合理的方法是可行的。国际公私财团 RESOLUTE (https://re-solute.eu/) 和 REsolution (https://re-solute.eu/resolution) 正在对 451 种不同的人类溶质载体中的每一种进行系统的功能分配（ SLC) 蛋白质，同时尝试对相关的主要遗传变异进行分类和解释。

SLCs 是促进和二级主动转运蛋白的超家族，按序列同源性细分，代表了一个与药物靶标来源（例如格列福嗪、选择性 5-羟色胺再摄取抑制剂）和药物处置（例如有机阴离子转运蛋白）相关的未充分研究的靶标类别. ^{1, 2}如果我们要参加这样一个目标课程并想快速“解锁”它，让科学界更广泛、更轻松地探索呢？如何以一种理性的、后基因组的方式进行呢？这就是 RESOLUTE 和 REsolution，两个由欧盟创新医学倡议 (IMI, https://www.ihi.europa.eu/) 和欧洲制药工业和协会联合会 (EFPIA) 资助的公私合作项目)，正在进行中。在这里，我们报告了这两个项目的状态，描述了对数据和试剂的新公共资源的访问，并简要描述了未来可能适用于类似目标类范围内努力的内容。